Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 8
Submit an article Journal homepage
311
Views
3
CrossRef citations to date
0
Altmetric
Articles

Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia

Weijia FuDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaORCID Iconhttps://orcid.org/0000-0001-7235-5853View further author information
ORCID Icon,
Aijie HuangDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaORCID Iconhttps://orcid.org/0000-0001-9689-1335View further author information
ORCID Icon,
Lili XuDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaView further author information
,
Yanni PengDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaView further author information
,
Lei GaoDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaView further author information
,
Li ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaView further author information
,
Jie ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaView further author information
,
Gusheng TangDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaView further author information
,
Jianmin YangDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaView further author information
&
Xiong NiDepartment of Hematology, Institute of Hematology, Changhai Hospital200433, Shanghai, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1956-1963 | Received 22 Dec 2021, Accepted 13 Feb 2022, Published online: 28 Feb 2022

References

  • Falini B, Brunetti L, Martelli MP. How I diagnose and treat NPM1-mutated AML. Blood. 2021;137(5):589–599.
  • Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92(4):519–532.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Yuan D, He X, Han X, et al. Comprehensive review and evaluation of computational methods for identifying FLT3-internal tandem duplication in acute myeloid leukaemia. Brief Bioinform. 2021;22(5):bbab099.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
  • Angenendt L, Rollig C, Montesinos P, et al. Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts. J Clin Oncol. 2019;37(29):2632–2642.
  • Micol JB, Boissel N, Renneville A, et al. The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication. Blood. 2009;114(20):4601–4602, author reply 4602–4603.
  • Wang Z, Guo M, Zhang Y, et al. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. Int J Lab Hematol. 2019;41(5):607–614.
  • Huang A, Chen Q, Fei Y, et al. Dynamic prediction of relapse in patients with acute leukemias after allogeneic transplantation: joint model for minimal residual disease. Int J Lab Hematol. 2021;43(1):84–92.
  • Paiva B, Vidriales MB, Sempere A, et al. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia. 2021;35(8):2358–2370.
  • Hu X, Wang B, Chen Q, et al. A clinical prediction model identifies a subgroup with inferior survival within intermediate risk acute myeloid leukemia. J Cancer. 2021;12(16):4912–4923.
  • Zhang Y, Zhang Y, Chen Q, et al. Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years. Ann Hematol. 2019;98(4):997–1007.
  • Zhang WP, Yang D, Song XM, et al. Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden. Biol Blood Marrow Transplant. 2013;19(4):653–660.
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
  • Eisfeld AK, Kohlschmidt J, Mims A, et al. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. Leukemia. 2020;34(12):3215–3227.
  • Straube J, Ling VY, Hill GR, et al. The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia. Blood. 2018;131(10):1148–1153.
  • Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2(20):2744–2754.
  • Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291.
  • Buccisano F, Maurillo L, Schuurhuis GJ, et al. The emerging role of measurable residual disease detection in AML in morphologic remission. Semin Hematol. 2019;56(2):125–130.
  • Mushtaq MU, Harrington AM, Chaudhary SG, et al. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2021;62(1):158–166.
  • Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024–3032.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.